Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Aug;62(2):205–208. doi: 10.1038/bjc.1990.261

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease.

N Rajaram 1, R J Tatake 1, S H Advani 1, S G Gangal 1
PMCID: PMC1971824  PMID: 2386735

Abstract

We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About 75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean percent NK activity of healthy donors--2 SD) in patients with lymphocyte depletion histologic grade of the disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL comparable to that of healthy donors.

Full text

PDF
205

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aghai E. Hodgkin disease: malignancy, inflammation and abnormal immunity. Leuk Res. 1986;10(11):1267–1270. doi: 10.1016/0145-2126(86)90332-2. [DOI] [PubMed] [Google Scholar]
  2. Berényi E., Surányi P., Pálóczi K., Szegedi G. Large granular lymphocytes, Leu 7 reactivity and natural killer cell function in peripheral blood of patients with Hodgkin's disease. Cancer Immunol Immunother. 1986;21(2):164–166. doi: 10.1007/BF00199866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Castelli M., Guadagni S., Bagnato A., Pistoia M. A., Carboni M., Sega E. Evaluation of carcinoembryonic antigen levels in gastric juice, stomach mucosa and plasma in high-risk and gastric cancer patients. Oncology. 1986;43(3):149–153. doi: 10.1159/000226354. [DOI] [PubMed] [Google Scholar]
  4. Dabholkar M., Advani S., Tatake R., Gangal S. Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission. Leuk Res. 1986;10(2):203–209. doi: 10.1016/0145-2126(86)90043-3. [DOI] [PubMed] [Google Scholar]
  5. Damle R. N., Tatake R. J., Advani S. H., Gangal S. G. Affinity of IL-2 receptors and proliferation of mitogen activated lymphocytes in Hodgkin's disease. Br J Cancer. 1990 Mar;61(3):404–406. doi: 10.1038/bjc.1990.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dawson M. M., Johnston D., Taylor G. M., Moore M. Lymphokine activated killing of fresh human leukaemias. Leuk Res. 1986;10(6):683–688. doi: 10.1016/0145-2126(86)90273-0. [DOI] [PubMed] [Google Scholar]
  7. Frydecka I. Natural killer cell activity during the course of disease in patients with Hodgkin's disease. Cancer. 1985 Dec 15;56(12):2799–2803. doi: 10.1002/1097-0142(19851215)56:12<2799::aid-cncr2820561215>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  8. Grimm E. A. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochim Biophys Acta. 1986 Dec 17;865(3):267–279. doi: 10.1016/0304-419x(86)90017-x. [DOI] [PubMed] [Google Scholar]
  9. Hawrylowicz C. M., Rees R. C., Hancock B. W., Potter C. W. Depressed spontaneous natural killing and interferon augmentation in patients with malignant lymphoma. Eur J Cancer Clin Oncol. 1982 Nov;18(11):1081–1088. doi: 10.1016/0277-5379(82)90087-6. [DOI] [PubMed] [Google Scholar]
  10. Joshi N. N., Mukhopadhyay R., Advani S. H., Gangal S. G. Production of interleukin-2 and expression of tac antigen in Hodgkin disease. Cancer Detect Prev Suppl. 1987;1:137–143. [PubMed] [Google Scholar]
  11. Karande A. A., Gulwani B., Advani S. H., Gangal S. G. Subpopulations of human T lymphocytes in patients with Hodgkin's disease before and after treatment. Neoplasma. 1982;29(2):149–159. [PubMed] [Google Scholar]
  12. Komiyama A., Kawai H., Yamada S., Kato M., Yanagisawa M., Miyagawa Y., Akabane T. A killing defect of natural killer cells with the absence of natural killer cytotoxic factors in a child with Hodgkin's disease. Blood. 1987 Jun;69(6):1686–1690. [PubMed] [Google Scholar]
  13. Levy S., Tempe J. L., Aleksijevic A., Giron C., Oberling F., Mayer S., Lang J. M. Depressed NK cell activity of peripheral blood mononuclear cells in untreated hodgkin's disease: enhancing effect of interferon in vitro. Scand J Haematol. 1984 Oct;33(4):386–390. doi: 10.1111/j.1600-0609.1984.tb00712.x. [DOI] [PubMed] [Google Scholar]
  14. Lotzová E. Effector immune mechanisms in cancer. Nat Immun Cell Growth Regul. 1985;4(6):293–304. [PubMed] [Google Scholar]
  15. Moghe M. V., Advani S. H., Gangal S. G. Demonstration of inhibitory factors affecting cell-mediated immunity in patients with Hodgkin's disease. Eur J Cancer. 1980 Jul;16(7):937–943. doi: 10.1016/0014-2964(80)90332-1. [DOI] [PubMed] [Google Scholar]
  16. Moghe M. V., Advani S. H., Gangal S. G. Suppressive effect of adherent mononuclear cells from peripheral blood of patients with Hodgkin's disease on PHA responsiveness. Indian J Exp Biol. 1981 Dec;19(12):1101–1106. [PubMed] [Google Scholar]
  17. Mukhopadhyaya R., Advani S. H., Gangal S. G. Effect of exogenous interleukins on in vitro responses of T lymphocytes from patients with Hodgkin disease. Cancer Detect Prev. 1987;10(5-6):445–451. [PubMed] [Google Scholar]
  18. Mukhopadhyaya R., Advani S. H., Gangal S. G. Functional evaluation of T-lymphocytes from peripheral blood and spleens in Hodgkin's disease. Br J Cancer. 1987 Dec;56(6):800–802. doi: 10.1038/bjc.1987.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mukhopadhyaya R., Advani S. H., Gangal S. G. Impairment of T lymphocyte colony formation in Hodgkin's disease: effect of soluble inhibitory factors on normal T lymphocyte colony formation potential. Acta Haematol. 1983;70(6):357–363. doi: 10.1159/000206793. [DOI] [PubMed] [Google Scholar]
  20. Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizoguchi H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood. 1986 Oct;68(4):938–948. [PubMed] [Google Scholar]
  21. Rajaram N., Tatake R. J., Advani S. H., Naik S. L., Gangal S. G. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia. Cancer Immunol Immunother. 1990;31(1):44–48. doi: 10.1007/BF01742494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Romagnani S., Ferrini P. L., Ricci M. The immune derangement in Hodgkin's disease. Semin Hematol. 1985 Jan;22(1):41–55. [PubMed] [Google Scholar]
  23. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  24. Rotstein S., Baral E., Blomgren H., Johansson B. In vitro radiosensitivity of the spontaneous cytotoxicity of blood lymphocytes in patients with untreated Hodgkin's disease. Eur J Cancer Clin Oncol. 1983 Oct;19(10):1405–1409. doi: 10.1016/0277-5379(93)90010-3. [DOI] [PubMed] [Google Scholar]
  25. Tatake R. J., Krishnan N., Rao R. S., Fakih A. R., Gangal S. G. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer. Int J Cancer. 1989 Apr 15;43(4):560–566. doi: 10.1002/ijc.2910430405. [DOI] [PubMed] [Google Scholar]
  26. Tursz T., Dokhelar M. C., Lipinski M., Amiel J. L. Low natural killer cell activity in patients with malignant lymphoma. Cancer. 1982 Dec 1;50(11):2333–2335. doi: 10.1002/1097-0142(19821201)50:11<2333::aid-cncr2820501119>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES